Dianosic, a Strasbourg, France-based startup specializing in innovative solutions for Ear, Nose and Throat (ENT) conditions, raised a first round of more than €1.5m ($1.63M) in capital and non-dilutive funding.
Backers included PAF Kapital, a group of business angels, Bpifrance Alsace, the Grand Est Region and two banks, Caisse d’Epargne Grand-Est Europe and Banque Populaire Rives de Paris.
The company intends to use the funds for the European launch of CAVI-T™, its intranasal bleeding treatment device, and pursue development of solutions in treatment of chronic sinusitis.
Created in July 2017 by Marc Augustin, Philippe Bastide and Pr Christian Debry, head of the ENT & Head and Neck Surgery Department of the Strasbourg University Hospital, Dianosic develops innovative solutions for the management of ENT conditions. Its first innovative device is the asymmetrical intranasal balloon, CAVI-T, which stops spontaneous or postoperative bleeding – hemostasis – with low pressure compression, adapting to the unique anatomy of the nasal cavity. The device was CE marked in February 2020. It is covered by a patent valid for France and it will soon be covered in Europe, the US, Japan and China. With its second medical device, the Active Resorbable Intranasal Scaffold (ARIS), currently under development, Dianosic aims to enable the management of chronic sinusitis, by delivering a steroid in a targeted manner to patients over a long-term period (12 months) without needing prior surgery, unlike current solutions.
Incubated by SEMIA, the company is supported by the ecosystem of the Grand Est region, the SATT Connectus, Bpifrance Alsace, Biovalley France, the Eurometropolis of Strasbourg and Innouvo/Cajuba Finance.